Literature DB >> 17459918

Establishment of a cottontail rabbit papillomavirus/HLA-A2.1 transgenic rabbit model.

Jiafen Hu1, Xuwen Peng, Lynn R Budgeon, Nancy M Cladel, Karla K Balogh, Neil D Christensen.   

Abstract

Three transgenic rabbit lines that express a well-characterized human major histocompatibility complex class I (MHC-I) gene (HLA-A2.1) have been established. All three lines carry the HLA-A2.1 heavy chain and are able to pass the transgene to their offspring with both the outbred and the inbred EIII/JC genetic background. HLA-A2.1 colocalizes exclusively with rabbit MHC-I on the cell surfaces. These HLA-A2.1 transgenic rabbits demonstrated infection patterns similar to those found after cottontail rabbit papillomavirus (CRPV) challenge when compared with results in normal rabbits, although higher regression rates were found in HLA-A2.1 transgenic rabbits. Because the CRPV genome can accommodate significant modifications, the CRPV/HLA-A2.1 rabbit model has the potential to be used to screen HLA-A2.1-restricted immunogenic epitopes from human papillomaviruses in the context of in vivo papillomavirus infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17459918      PMCID: PMC1933279          DOI: 10.1128/JVI.00200-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.

Authors:  Luisa L Villa; Ronaldo L R Costa; Carlos A Petta; Rosires P Andrade; Kevin A Ault; Anna R Giuliano; Cosette M Wheeler; Laura A Koutsky; Christian Malm; Matti Lehtinen; Finn Egil Skjeldestad; Sven-Eric Olsson; Margareta Steinwall; Darron R Brown; Robert J Kurman; Brigitte M Ronnett; Mark H Stoler; Alex Ferenczy; Diane M Harper; Gretchen M Tamms; Jimmy Yu; Lisa Lupinacci; Radha Railkar; Frank J Taddeo; Kathrin U Jansen; Mark T Esser; Heather L Sings; Alfred J Saah; Eliav Barr
Journal:  Lancet Oncol       Date:  2005-05       Impact factor: 41.316

2.  Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial.

Authors:  Gregory A Poland; Robert M Jacobson; Laura A Koutsky; Gretchen M Tamms; Radha Railkar; Judith F Smith; Janine T Bryan; Paul F Cavanaugh; Kathrin U Jansen; Eliav Barr
Journal:  Mayo Clin Proc       Date:  2005-05       Impact factor: 7.616

Review 3.  Cottontail rabbit papillomavirus (CRPV) model system to test antiviral and immunotherapeutic strategies.

Authors:  Neil D Christensen
Journal:  Antivir Chem Chemother       Date:  2005

4.  Protection of rabbits from viral challenge by gene gun-based intracutaneous vaccination with a combination of cottontail rabbit papillomavirus E1, E2, E6, and E7 genes.

Authors:  R Han; N M Cladel; C A Reed; X Peng; N D Christensen
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

5.  The cottontail rabbit papillomavirus model of high-risk HPV-induced disease.

Authors:  Janet L Brandsma
Journal:  Methods Mol Med       Date:  2005

Review 6.  Prophylactic human papillomavirus vaccines.

Authors:  Douglas R Lowy; John T Schiller
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

7.  Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations.

Authors:  Soumyajit Majumdar; Yasser E Nashed; Kunal Patel; Ritesh Jain; Motoki Itahashi; Donna M Neumann; James M Hill; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2005-12       Impact factor: 2.671

8.  Papillomas and carcinomas in transgenic rabbits carrying EJ-ras DNA and cottontail rabbit papillomavirus DNA.

Authors:  X Peng; R O Olson; C B Christian; C M Lang; J W Kreider
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

9.  Highly attenuated HTLV type Ienv poxvirus vaccines induce protection against a cell-associated HTLV type I challenge in rabbits.

Authors:  G Franchini; J Tartaglia; P Markham; J Benson; J Fullen; M Wills; J Arp; G Dekaban; E Paoletti; R C Gallo
Journal:  AIDS Res Hum Retroviruses       Date:  1995-02       Impact factor: 2.205

10.  Large cutaneous rabbit papillomas that persist during cyclosporin A treatment can regress spontaneously after cessation of immunosuppression.

Authors:  Jiafen Hu; Xuwen Peng; Nancy M Cladel; Martin D Pickel; Neil D Christensen
Journal:  J Gen Virol       Date:  2005-01       Impact factor: 5.141

View more
  9 in total

1.  Mucosally delivered peptides prime strong immunity in HLA-A2.1 transgenic rabbits.

Authors:  Jiafen Hu; Nancy Cladel; Karla Balogh; Neil Christensen
Journal:  Vaccine       Date:  2010-03-21       Impact factor: 3.641

2.  High incidence of spontaneous cataracts in aging laboratory rabbits of an inbred strain.

Authors:  Xuwen Peng; Sara Roshwalb; Timothy K Cooper; Heather Zimmerman; Neil D Christensen
Journal:  Vet Ophthalmol       Date:  2014-08-14       Impact factor: 1.644

3.  Using HLA-A2.1 Transgenic Rabbit Model to Screen and Characterize New HLA-A2.1 Restricted Epitope DNA Vaccines.

Authors:  Jiafen Hu; Todd D Schell; Xuwen Peng; Nancy M Cladel; Karla K Balogh; Neil D Christensen
Journal:  J Vaccines Vaccin       Date:  2010-08-20

Review 4.  An overview of the lagomorph immune system and its genetic diversity.

Authors:  Ana Pinheiro; Fabiana Neves; Ana Lemos de Matos; Joana Abrantes; Wessel van der Loo; Rose Mage; Pedro José Esteves
Journal:  Immunogenetics       Date:  2015-09-23       Impact factor: 2.846

5.  Vaccine generated immunity targets an HPV16 E7 HLA-A2.1-restricted CD8(+) T cell epitope relocated to an early gene or a late gene of the cottontail rabbit papillomavirus (CRPV) genome in HLA-A2.1 transgenic rabbits.

Authors:  Callie E Bounds; Jiafen Hu; Nancy M Cladel; Karla Balogh; Neil D Christensen
Journal:  Vaccine       Date:  2010-12-16       Impact factor: 3.641

Review 6.  The rabbit papillomavirus model: a valuable tool to study viral-host interactions.

Authors:  Nancy M Cladel; Xuwen Peng; Neil Christensen; Jiafen Hu
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-05-27       Impact factor: 6.237

7.  Long-peptide therapeutic vaccination against CRPV-induced papillomas in HLA-A2.1 transgenic rabbits.

Authors:  Jiafen Hu; Lynn R Budgeon; Karla K Balogh; Xuwen Peng; Nancy M Cladel; Neil D Christensen
Journal:  Trials Vaccinol       Date:  2014

Review 8.  Rabbit Models for Studying Human Infectious Diseases.

Authors:  Xuwen Peng; John A Knouse; Krista M Hernon
Journal:  Comp Med       Date:  2015-12       Impact factor: 0.982

Review 9.  Modeling HPV-Associated Disease and Cancer Using the Cottontail Rabbit Papillomavirus.

Authors:  Nancy M Cladel; Jie Xu; Xuwen Peng; Pengfei Jiang; Neil D Christensen; Zhi-Ming Zheng; Jiafen Hu
Journal:  Viruses       Date:  2022-09-04       Impact factor: 5.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.